AstraZeneca-Merck cancer drug Lynparza wins approval in China

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, AstraZeneca and Merck said.

New Delhi: AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first-line treatment for a form of ovarian cancer.

The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.

Read Also: AstraZeneca cancer drug Imfinzi gets USFDA priority review

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

Read Also: AstraZeneca leukemia drug Calquence gets USFDA okay